1. Home
  2. BCLI vs ICCT Comparison

BCLI vs ICCT Comparison

Compare BCLI & ICCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCLI
  • ICCT
  • Stock Information
  • Founded
  • BCLI 2000
  • ICCT 1992
  • Country
  • BCLI United States
  • ICCT United States
  • Employees
  • BCLI N/A
  • ICCT N/A
  • Industry
  • BCLI Biotechnology: Biological Products (No Diagnostic Substances)
  • ICCT Computer Software: Prepackaged Software
  • Sector
  • BCLI Health Care
  • ICCT Technology
  • Exchange
  • BCLI Nasdaq
  • ICCT Nasdaq
  • Market Cap
  • BCLI 6.4M
  • ICCT 5.2M
  • IPO Year
  • BCLI N/A
  • ICCT N/A
  • Fundamental
  • Price
  • BCLI $1.21
  • ICCT $0.16
  • Analyst Decision
  • BCLI Strong Buy
  • ICCT
  • Analyst Count
  • BCLI 1
  • ICCT 0
  • Target Price
  • BCLI $30.00
  • ICCT N/A
  • AVG Volume (30 Days)
  • BCLI 118.2K
  • ICCT 5.9M
  • Earning Date
  • BCLI 11-14-2024
  • ICCT 11-29-2024
  • Dividend Yield
  • BCLI N/A
  • ICCT N/A
  • EPS Growth
  • BCLI N/A
  • ICCT N/A
  • EPS
  • BCLI N/A
  • ICCT N/A
  • Revenue
  • BCLI N/A
  • ICCT $10,266,331.00
  • Revenue This Year
  • BCLI N/A
  • ICCT N/A
  • Revenue Next Year
  • BCLI N/A
  • ICCT N/A
  • P/E Ratio
  • BCLI N/A
  • ICCT N/A
  • Revenue Growth
  • BCLI N/A
  • ICCT 34.56
  • 52 Week Low
  • BCLI $1.05
  • ICCT $0.15
  • 52 Week High
  • BCLI $11.85
  • ICCT $3.20
  • Technical
  • Relative Strength Index (RSI)
  • BCLI 23.69
  • ICCT 30.94
  • Support Level
  • BCLI $1.05
  • ICCT $0.17
  • Resistance Level
  • BCLI $1.95
  • ICCT $0.19
  • Average True Range (ATR)
  • BCLI 0.20
  • ICCT 0.04
  • MACD
  • BCLI -0.00
  • ICCT 0.00
  • Stochastic Oscillator
  • BCLI 15.84
  • ICCT 3.55

About BCLI Brainstorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.

About ICCT iCoreConnect Inc. Common stock

iCoreConnect Inc develops and markets secure cloud-based HIPAA compliant software services focused on compliance, workflow/productivity, and electronic health records systems. Its core services technology can be adopted to other vertical markets that require a high degree of secure data communication, such as the legal, financial, and education fields. It markets secure HIPAA compliant cloud-based software as a service (SaaS) offering under the names of iCoreExchange, iCoreCodeGenius, iCoreSecure, iCoreMD, iCoreDental, iCoreMobile, iCoreHuddle, iCoreRx, iCorePDMP, iCoreEPCS, and iCorePay. The company's software is sold under annual recurring revenue subscriptions. The company has a single reporting segment for reporting purposes focused on the North American market.

Share on Social Networks: